Mazdutide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Mazdutide
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist in late-stage clinical development showing compelling weight loss data in trials conducted primarily in Asia. It targets both energy intake (via GLP-1) and energy expenditure (via glucagon), a mechanistically differentiated approach from semaglutide. Phase III trials report 15–18% body weight reduction. It is not yet FDA-approved but may reach Western markets by 2026–2027.
Science
Mechanism of Action
Simultaneous activation of GLP-1 and glucagon receptors produces appetite suppression via the hypothalamus while glucagon signaling increases hepatic glucose output and thermogenic energy expenditure.
Dosing
Typical Protocol
3–9 mg subcutaneous injection once weekly; currently available through research access outside the US.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Mazdutide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.